Federal Register / Vol. 66, No. 12 / Thursday, January 18, 2001 / Notices 4847

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the grant

applications and/or contract proposals,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Board of Regents of

the National Library of Medicine.

Date: February 27–28, 2001.

Open: February 27, 2001, 9:00 am to 4:40

pm.

Agenda: Administrative Reports and

Program Discussion.

Place: National Library of Medicine, Board

Room, Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Closed: February 27, 2001, 4:40 pm to 5:00

pm.

Agenda: To review and evaluate grant

applications.

Place: National Library of Medicine, Board

Room, Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Open: February 28, 2001, 9:15 am to 11:30

am.

Agenda: Administrative Reports and

Program Discussion.

Place: National Library of Medicine, Board

Room, Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Contact Person: Donald A.B. Lindberg, MD,

Director, National Library of Medicine,

National Institutes of Health, PHS, DHHS,

Bldg 38, Room 2E17B, Bethesda, MD 20894.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.879, Medical Library

Assistance, National Institutes of Health,

HHS)

Dated: January 9, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–1458 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Method for Preparing 17αAcetoxy-11β-(4-,N-Dimethylaminophyl)-

19-Norpregna-4, 9-Diene-3,20-Dione,

Intermediates Useful in the Method,

and Methods for the Preparation of

Such Intermediates

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 08/413,755, filed

March 30, 1995, issuing as U.S. Patent

5,929,262 entitled, ‘‘Method for

Preparing 17α-Acetoxy-11β-(4-N,NDimethylaminophyl)-19-Norpregna-4, 9-

Diene-3,20-Dione, Intermediates Useful

in the Method, and Methods for the

Preparation of such Intermediates’’ to

HRA Pharma, a corporation of France,

having a place of business in Paris,

France. The patent rights in this

invention have been assigned to the

United States of America, as represented

by the Department of Health and Human

Services.

DATES: Only written comments and/or

application for a license which are

received by the NIH Office of

Technology Transfer on or before April

18, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Dennis H. Penn, Pharm.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7056, ext. 211; Facsimile: (301) 402–

0220.

SUPPLEMENTARY INFORMATION: In an

effort to develop an efficacious

treatment for human reproductive

disorders this invention describes

methods for the synthesis of 17αAcetoxy-11β-(4-N,NDimethylaminophyl)-19-Norpregna-4,9-

Diene-3,20-Dione Intermediates Useful

in the Method, and Methods for the

Preparation of such Intermediates This

compound may have utility in treating

human reproductive disorders and

hormone sensitive tumors.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 90 days from the date of this

published Notice, NIH received written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the

use of the invention for the synthesis

17α-Acetoxy-11β-(4-N,NDimethylaminophyl)-19-Norpregna-4, 9-

Diene-3,20-Dione and intermediates

useful in the method of synthesis and

preparation of such intermediates.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–1465 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Orally Active Derivatives of

1,3,5(10)-Estratriene

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Series No. 08/122,853, filed

September 17, 1993, issuing as U.S.

Patent 5,554,603 on September 10, 1996

entitled, ‘‘Orally Active Derivatives of

1,3,5(10)-Estratriene’’ to the R.W.

Johnson Pharmaceutical Research

Institute, a corporation of Delaware,

having a place of business in Raritan,

New Jersey. The patent rights in this

invention have been assigned to the

4848 Federal Register / Vol. 66, No. 12 / Thursday, January 18, 2001 / Notices

United States of America, as represented

by the Department of Health and Human

Services.

DATES: Only written comments and/or

application for a license which are

received by the NIH Office of

Technology Transfer on or before March

19, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Dennis H. Penn, Pharm.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7056, ext. 211; Facsimile: (301) 402–

0220.

SUPPLEMENTARY INFORMATION: In an

effort to develop an efficacious

treatment for human reproductive

disorders this invention describes orally

active derivatives of 1,3,5(10)-

estratriene. This compound may have

utility as a contraceptive and as an

estrogen replacement for the treatment

and prevention of postmenopausal

conditions.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH received written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the

use of the invention for the

development of pharmaceutical

compounds for use as a contraceptive

and for treatment and prevention of

postmenopausal conditions.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–1464 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Prophylactic and/or

Therapeutic Vaccine Against

Pseudomonas Aeruginosa, Chlamydia,

Trachomatis and Mycoplasma

Pneumonia

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a limited field of use

exclusive worldwide license to practice

the inventions embodied in U.S. Serial

Number 09/462,682, filed January 10,

2000 (claiming priority to U.S.

Provisional Patent Application Serial

No. 60/052,375, filed July 11, 1997),

entitled ‘‘Pseudomonas exotaxin A-Like

Chimeric Immunogens’’ and U.S. Serial

Number 09/462,713 filed May 12, 2000

(claiming priority to U.S. Provisional

Patent Application Serial No. 60/

056,924, filed July 11, 1997), entitled

‘‘Pseudomonas Exotoxin A-like Chimera

Immunogens for eliciting a secretory

IgA-Mediated Immune Response’’ to

Trinity BioSystems, L.L.C. of Los Altos

Hills, California, U.S.A. The United

States as represented by the Department

of Health and Human Services is an

assignee of these patent rights.

DATES: Only written comments and/or

applications for a license which are

received by NIH on or before March 19,

2001 will be considered.

ADDRESSES: Requests for a copy of these

patent applications, inquiries,

comments, and other materials relating

to the contemplated license should be

directed to: Carol A. Salata, Technology

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804;

Telephone: (301) 496–7735 ext. 232;

Facsimile: (301) 402–0220; E-mail:

salatac@OD.NIH.GOV. A signed

Confidential Disclosure Agreement

(CDA) may be required to receive copies

of the patent applications.

SUPPLEMENTARY INFORMATION: The patent

applications describe the use of

Pseudomonas exotoxin A-like chimeric

immunogens in which a non-native

epitope is inserted into a domain. These

immunogens are useful to elicit

humoral, cell-mediated and mucosal

immune responses against the nonnative epitope.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7.

It is anticipated that this license may

be limited to the field of use as a

prophylactic and/or therapeutic vaccine

against Pseudomonas aeruginosa,

Chlamydia trachomatis and

Mycoplasma pneumoniae. Trinity

BioSystems will use Pseudomonas

exotoxin A to target and deliver

pathogen peptide epitopes wherein said

pathogen peptide epitopes are inserted

into or replace a domain of

Pseudomonas exotoxin A.

This propsective exclusive license

may be granted unless within 60 days

from the date of this published notice,

NIH receives written evidence and

argument that establishes that the grant

of the license would not be consistent

with the requirements of 35 U.S.C. 209

and 37 CFR 404.7.

Applications for a license filed in

response to this notice will be treated as

objections to the grant of the

contemplated license. Comments and

objections submitted in response to this

notice will not be made available for

public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–1463 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Office for Women’s Services; Notice of

Meeting

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the Advisory Committee for Women’s

Services of the Substance Abuse and

Mental Health Services Administration

(SAMHSA) on Friday January 26, 2001.

The meeting of the Advisory

Committee for Women’s Services will

include a discussion of policy and

program issues relating to women’s

substance abuse and mental health

service needs; the SAMHSA fiscal year

2001 budget; specific Committee goals

for the current year, planning

discussions for SAMHSA’s Third

National Conference on Women,